Entries |
Document | Title | Date |
20090054529 | Flow Path Conditioner System - Compositions ( | 02-26-2009 |
20090186948 | USE OF COMBINATIONS OF METHYL ETHYL KETONE PEROXIDE BY SPRAYING - Composition of Methyl Ethyl Ketone Peroxide as biocide, applied by spraying, for human and veterinary hygiene; of utility in the private sphere and in public health and, particularly, conserving the organic matter of its natural surface decomposition due to the passage of time until the collection for treatment and/or elimination, preventing proliferation of organisms accompanying said situation and the risk of intrinsic infectious contagion. The compositions permitting such biocidal action are a mixture of from 0.01 to 14% Methyl Ethyl Ketone Peroxide, from 1 to 60% glycols or alcohols, from 1 to 60% water and, optionally, from 0 to 10% stabilisers, colourants, scents and/or other additives, from 0 to 10% surfactants and from 0 to 10% acids, conferring on the product a solubility permitting its spraying to act as antiseptic for healthy skin, disinfectant for surfaces and for the maintenance of organic matter and its residues. | 07-23-2009 |
20100216891 | AROMATIC ANTIHYPERTENSIVE AGENT, AND METHOD FOR LOWERING BLOOD PRESSURE IN MAMMALS - The present invention provides an antihypertensive agent having a superior antihypertensive action, and a method for lowering blood pressure in mammals by inhalation of such an antihypertensive agent through the nostril. | 08-26-2010 |
20100234474 | Method and Composition for Evenly Applying Water Soluble Actives - A method and composition for evenly applying water soluble actives is described. The method includes applying a composition with a HIPE to skin and generating a film having a hydrophilic surface so that composition and active can be evenly applied. | 09-16-2010 |
20110034563 | COMPARTMENT-SPECIFIC PLANT EXTRACT COMBINATION OF GINKGO BILOBA EXTRACT AND GINSENG EXTRACT HAVING A TANDEM EFFECT - The invention relates to a plant extract combination of | 02-10-2011 |
20110230564 | ANT4 INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - The invention relates to methods for inducing male contraception and to methods of treating cell proliferation related disorders or diseases, such as cancer. The invention further relates to pharmaceutical compositions for inducing male contraception and for treating cell proliferation related disorders or diseases. | 09-22-2011 |
20120046366 | Extractions of Fixed Oil and Thymoquinone Rich Fractions (TQRF) - The present invention reported that SFE is suitable for | 02-23-2012 |
20120136066 | Glomerulonephritis Treatment - A compound of formula (I) R-L-CO—X (I) (wherein R is a C | 05-31-2012 |
20120172453 | METHODS FOR TREATING NEURODEGENERATIVE DISEASES - This invention relates to the 5-cis and 5-trans isomers of geranylgeranyl acetone, preferably such synthetic isomers, and pharmaceutical compositions containing such isomers. Other aspects of this invention relate to the use of geranylgeranyl acetone and its isomers in methods for inhibiting neural death, increasing neural activity, and increasing axon growth and cell viability. Geranylgeranyl acetone is a known anti-ulcer drug used commercially and in clinical situations. GGA has also been shown to exert cytoprotective effects on a variety of organs, such as the eye, brain, and heart. | 07-05-2012 |
20130245126 | GERANYLGERANYLACETONE FORMULATIONS AND RETINAL DELIVERY THEREOF - Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations. | 09-19-2013 |
20130245127 | RHEUMATOID ARTHRITIS TREATMENT - A compound of formula (I) | 09-19-2013 |
20130303624 | OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE - An ophthalmic composition comprising geranylgeranylacetone which
| 11-14-2013 |
20130303625 | AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE - A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which
| 11-14-2013 |
20130303626 | OPHTHALMIC COMPOSITION - An ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent has an advantage that the loss of the geranylgeranylacetone content during long-term storage is very little. This is because of reduced adsorption of geranylgeranylacetone to a wall of an ophthalmic container. The ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent also has an advantage that adsorption of geranylgeranylacetone to a contact lens is little. Further, the ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent hardly becomes white turbid even when stored at low temperature. | 11-14-2013 |
20130303627 | OPHTHALMIC COMPOSITION - An ophthalmic composition comprising geranylgeranylacetone and a fat-soluble antioxidant has an advantage that adsorption of geranylgeranylacetone to a wall of a container is remarkably reduced and thereby the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the composition is remarkably reduced. Adsorption of the fat-soluble antioxidant to a wall of a container is also reduced due to combination with geranylgeranylacetone. | 11-14-2013 |
20130324613 | USE OF POLYUNSATURATED KETONES FOR THE TREATMENT OF PSORIASIS - Psoriasis is a common, chronic, inflammatory skin disorder. This invention provides the use of a compound of formula (I) R—CO—X (Wherein R is a C | 12-05-2013 |
20130331458 | KIT OF OPHTHALMIC COMPOSITION - An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, | 12-12-2013 |
20140045948 | KIT OF OPHTHALMIC COMPOSITION - An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little. | 02-13-2014 |
20140107219 | LOCAL ANAESTHETIC - In one aspect, there is provided heptanone (e.g. 2-, 3- or 4-heptanone) or a salt thereof for use as a local anaesthetic. In another aspect, there is provided a pharmaceutical composition comprising heptanone (e.g. 2-, 3- or 4-heptanone) or a salt thereof and one or more pharmaceutically acceptable carriers, excipients or diluents. Also provided is use of heptanone (e.g. 2-, 3- or 4-heptanone) or a salt thereof in the preparation of a medicament for use as a local anaesthetic. Further provided is a method of treating a mammalian subject in need of local anaesthesia, comprising administering a pharmaceutical composition comprising heptanone (e.g. 2-, 3- or 4-heptanone) or a salt thereof in an effective amount to a region of the subject in need of local anaesthesia. | 04-17-2014 |
20140128475 | AGENT FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF RETINAL DISEASE - A prophylactic, ameliorating or therapeutic agent for a retinal disease, the agent comprising geranylgeranylacetone which | 05-08-2014 |
20140171516 | GERANYLGERANYLACETONE FORMULATIONS - Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations. | 06-19-2014 |
20140171517 | 2-MERCAPTO-5-METHYL-4-HEPTANONE AND ITS USE IN FLAVOR AND FRAGRANCE COMPOSITIONS - The present invention is directed to a novel compound, 2-mercapto-5-methyl-4-heptanone, a process of augmenting, enhancing or imparting taste to a material selected from the group consisting of a foodstuff, a chewing gum, a medicinal product, and toothpaste comprising the step of incorporating an olfactory acceptable amount of 2-mercapto-5-methyl-4-heptanone, and a process of improving, enhancing or modifying a fragrance formulation through the addition of an olfactory acceptable amount of 2-mercapto-5-methyl-4-heptanone. | 06-19-2014 |
20140187646 | Geranylgeranylacetone formulations and retinal and systemic delivery thereof - Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations. | 07-03-2014 |
20140194527 | GERANYLGERANYLACETONE FORMULATIONS AND RETINAL DELIVERY THEREOF - Provided herein is a pharmaceutical formulation comprising at least one geranylgeranyl acetone in the form of an eye drop. Also provided herein are methods of treating neural diseases or disorders by administering such pharmaceutical formulations. | 07-10-2014 |
20140194528 | USAGE OF SODIUM HOUTTUYFONATE ON INHIBITING IDIOPATHIC PULMONARY FIBROSIS AND BLEOMYCIN INDUCED PULMONARY FIBROSIS - The present invention relates to a synthetic compound and its therapeutic uses. More particularly, it relates to a compound, Sodium Houttuyfonate, that is an addition compound of sodium bisulfite and houttuynin, and its biological activity of inhibiting idiopathic pulmonary fibrosis and bleomycin induced pulmonary fibrosis | 07-10-2014 |
20140243419 | MUCOSALLY-APPLIED AGENT FOR PREVENTION, AMELIORATION OR TREATMENT OF RETINAL DISEASE - Application of a pharmaceutical preparation comprising geranylgeranylacetone to the mucosa of, for example, the eye, nose, oral cavity or pharynx can efficiently prevent, ameliorate or treat retinal diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration, and diabetic retinopathy. | 08-28-2014 |
20140256824 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF GLOMERULONEPHRITIS - The invention provides compositions and methods for the treatment of glomerulonephritis. In one embodiment, the invention provides a compound of formula (I) | 09-11-2014 |
20140275280 | Therapeutic uses of geranylgeranyl acetone and derivatives thereof - Provide herein are methods of treating inflammatory bowel disease with geranylgeranyl acetone (GGA) and/or derivatives thereof. Also provided are methods of treating chronic liver disease (CLD) with geranylgeranyl acetone (GGA) and/or derivatives thereof. Still further are provided methods for treating other hepatic and cardiac disorders. | 09-18-2014 |
20140275281 | Geranylgeranyl acetone and derivatives thereof for intranasal administration - Provide herein are intranasal compositions which include geranylgeranyl acetone (GGA) and/or derivatives thereof and methods for treating a neural disease, disorder or condition with the same. | 09-18-2014 |
20140275282 | Treating osteopenia and related disorders with geranylgeranyl acetone and derivatives thereof - Provide herein are methods for treating osteopenia with geranylgeranyl acetone (GGA) and derivatives thereof and compositions useful for the same. | 09-18-2014 |
20140336267 | UTILIZATION OF THE FUNCTION OF RARE SUGAR AS PROMOTER FOR THE MIGRATION OF GLUCOKINASE FROM NUCLEUS TO CYTOPLASM - A composition for treating disordered conditions in association with glucokinase activity contains a glucokinase-activating substance as the active ingredient. A promoting agent of glucokinase transfer from nucleus to cytoplasm contains D-psicose and/or D-tagatose as the active ingredient or a composition for preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions is in a form selected from a group consisting of food additives, food materials, drinks and foods, health drinks and foods, pharmaceutical product and feeds in blend with D-psicose and/or D-tagatose as the active ingredient for use in preventing the onset of disordered conditions in association with glucokinase activity or for therapeutically treating the disordered conditions, which are selected from impaired glucose tolerance, type 2 diabetes mellitus, insulin resistance, abnormal lipidemia, the metabolic syndrome and obesity. | 11-13-2014 |
20140350119 | OPHTHALMIC COMPOSITION COMPRISING GERANYLGERANYLACETONE - An ophthalmic composition comprising geranylgeranylacetone which
| 11-27-2014 |
20150025154 | OPHTHALMIC COMPOSITION - An ophthalmic composition comprising geranylgeranylacetone and a fat-soluble antioxidant has an advantage that adsorption of geranylgeranylacetone to a wall of a container is remarkably reduced and thereby the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the composition is remarkably reduced. Adsorption of the fat-soluble antioxidant to a wall of a container is also reduced due to combination with geranylgeranylacetone. | 01-22-2015 |
20150065583 | Antimicrobially Active Compositions - Compositions ( | 03-05-2015 |
20150290144 | DERMATITIS TREATMENT - A compound of formula (I) | 10-15-2015 |
20160089345 | KIT OF OPHTHALMIC COMPOSITION - An ophthalmic composition kit comprising an ophthalmic container holding an ophthalmic composition comprising geranylgeranylacetone, the ophthalmic container having a surface in contact with the ophthalmic composition, the surface being at least partially or wholly made of a container material selected from the group consisting of a polyolefin, an acrylic acid resin, a terephthalic acid ester, a polycarbonate, a polymethylterpene, a fluorine resin and a glass, the ophthalmic composition kit having an advantage that the loss of the geranylgeranylacetone content or decrease in the geranylgeranylacetone concentration in the ophthalmic composition is very little. | 03-31-2016 |
20160100597 | TREATMENT OF POTATOES AND ROOT VEGETABLES DURING STORAGE - The turgidity of potato tubers and other root vegetables is improved, maintained, or restored and/or the greening of potato tubers is delayed, prevented or inhibited and/or internal diseases caused by fungi and bacteria are prevented or treated by the application of one or more α,β-unsaturated aliphatic aldehydes and ketones, C3 to C14 aliphatic aldehydes and ketones, and/or C3 to C7 saturated or unsaturated primary and secondary aliphatic alcohols. | 04-14-2016 |
20160136275 | OPHTHALMIC COMPOSITION - An ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent has an advantage that the loss of the geranylgeranylacetone content during long-term storage is very little. This is because of reduced adsorption of geranylgeranylacetone to a wall of an ophthalmic container. The ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent also has an advantage that adsorption of geranylgeranylacetone to a contact lens is little. Further, the ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent hardly becomes white turbid even when stored at low temperature. | 05-19-2016 |
20160151305 | AGENT OR METHOD FOR TREATEMENT AND/OR PREVENTION OF ACCELERATED ENERGY EXPENDITURE AND/OR DIMINISHED ENERGY EXPENDITURE FUNCTIONALITY | 06-02-2016 |
20180021269 | USES OF HYDROXYBENZOPHENONE IN PREPARATION OF ANTIVIRAL AND ANTITUMOR DRUGS | 01-25-2018 |